2/2 The list will be announced later today at the @technology Tech Summit and our CEO and co-founder @genemodeller will be on stage to discuss it, and the UK environment for life sciences and start-ups in general at 1.35pm. You can watch live here: https://t.co/JuXSeAEe2b
1/2 We have been named in @BloombergUK 's 25 UK Startups to Watch! The list is drawn from every business sector and more than 1500 companies applied. We're thrilled that the Bloomberg Editors selected us as one of the UK's most innovative businesses https://t.co/RTE1k77HNm
This paper (https://t.co/0iPcfBbZba), which had been on MedRXIV for a while 🐌, has finally been published today and has been generating quite a negative buzz in the press. It takes a bold stance against using polygenic risk in healthcare. 👇
Today, our CEO and co-founder @genemodeller received the @QMULWHRI prize for Outstanding Contribution to Science - well deserved and many congratulations Peter!
Our CEO, Peter Donnelly, is speaking on the Leaders Stage at the Health Summit today in @LondonTechWeek Join him, @longmiremd and Chair @jamesosh to hear more about how genomics is set to transform clinical trials https://t.co/aoQCtt1mPZ #LTW2023
It's #WorldCancerDay tomorrow.
Polygenic risk scores can find women who are at high risk of breast cancer.
Many of these women are currently invisible to healthcare systems, but we are working to help identify them, and get them access to screening.
#Genomics
“We are aiming for personalised prevention to become routine in the health service in five or 10 years’ time" - @genemodeller
📰 UK to embark on groundbreaking new #genomics projects
✏️ @clivecookson@FT
https://t.co/rfRVmyV3b0
Latest in our blog: Integration of a #PolygenicRiskScore in #PrimaryCare described as straightforward by >90% of GPs. Read about it at: https://t.co/m1N3QJSpUC
@Genomicsplc
The primary outcome was to see how practical it was to incorporate genetic information into QRISK, and then use it to guide management and treatment decisions.
#MedTwitter#Genomics
🧵4/4
HEART enrolled 836 patients aged 45-64 who were offered PRS integrated risk testing alongside their NHS health check.
Of these, 824 successfully completed the study, including follow-up.
🧵3/4
HEART is a world-first study, investigating the use of polygenic risk score testing in the prevention of cardiovascular disease in NHS clinical practice
We're happy to report significant, positive results from the pilot. Read the full story here ➡️ https://t.co/4yedYX0g16
🧵1/4
Great to see coverage of our HEART study. GP-led by @ahmetfuat17 HEART showed genetics can be used in day-to-day practice with a positive impact in the prevention of common diseases like CVD. Personalised prevention- better for patients, doctors and health systems like the NHS
We have been testing our approach with @NHSnecs and GP practices in the North of England in our HEART study, led by @AhmetFU38380786.
We will be presenting results from HEART soon.
#WorldHeartDay2022#UseHeart
https://t.co/gfNipIRRob
It's #WorldHeartDay 🫀
At Genomics, we think better prevention is key to reducing cardiovascular disease-related deaths.
To improve prevention, we need to better ways to identify those most at risk so we can get them right preventative care and treatment.
2/2 For more on our new paper “
@UK_Biobank release and systematic evaluation of optimised polygenic risk scores for 53 diseases and quantitative traits” including a full tweetorial, go to our colleague and joint senior author
@mikeweale's thread here: https://t.co/qaTixtbS3w
1/2 Genetics plays a big role in our risk of common diseases not just rare ones. Accurate polygenic risk scores #PRS capture this + can help us reduce it. @Genomicsplc we have world-leading PRS for more than 50 conditions. See our latest paper for details: https://t.co/5gmCHDmY7S